Non-consolidated Financial Results for the Six Months Ended June 30, 2026 (Under Japanese GAAP)8/14 16:00TDnetPDF(273KB)
Notice Regarding the First Patient Dosed in the Phase I/II company-sponsored Clinical Trial of HS-005 (Catheter Administration) for Cardiac Remuscular6/12 14:00TDnetPDF(294KB)
Notice Regarding Phase I/II Clinical Trial (LAPiS Study) Analysis Results for Allogeneic iPS Cell-derived Cardiomyocyte Spheroids (HS-001)6/1 16:00TDnetPDF(86KB)
Non-consolidated Financial Results for the Three Months Ended March 31, 2026(Under Japanese GAAP) May5/15 16:00TDnetPDF(242KB)
Notice of Introduction of Executive Officer System and Changes in Directors of the Board2/25 15:30TDnetPDF(175KB)